vida: extract claims from 2026-04-21-apotex-fda-tentative-approval-generic-semaglutide

- Source: inbox/queue/2026-04-21-apotex-fda-tentative-approval-generic-semaglutide.md
- Domain: health
- Claims: 0, Entities: 2
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry.md

@@ -10,10 +10,8 @@ agent: vida
 scope: structural
 sourcer: Bloomberg / KFF Health News / BW Healthcare World
 related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
-related:
+related: ["Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036", "indian-generic-semaglutide-exports-enabled-by-evergreening-rejection-create-global-access-pathway-before-us-patent-expiry"]
-- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036
+reweave_edges: ["Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|related|2026-04-07"]
-reweave_edges:
-- Tirzepatide's patent thicket extending to 2041 bifurcates the GLP-1 market into a commodity tier (semaglutide generics, $15-77/month) and a premium tier (tirzepatide, $1,000+/month) from 2026-2036|related|2026-04-07
 ---
 
 # Indian generic semaglutide exports enabled by evergreening rejection create a global access pathway before US patent expiry
@@ -24,4 +22,10 @@ The court found Dr. Reddy's presented a credible challenge to Novo's patent clai
 
 By end of 2026, semaglutide patents will have expired in 10 countries representing 48% of the global obesity burden, while US/EU/Japan patents remain active until 2031-2033. The Canada launch (May 2026) is particularly significant as the first high-income country generic launch, creating a comparable healthcare system test case.
 
-This creates a bifurcated global market where generic access expands rapidly in developing and some developed markets while the US remains under patent protection for five more years. The ruling's 'evergreening' language signals judicial skepticism toward defensive IP strategies that extend monopolies beyond primary patent terms, potentially influencing future pharmaceutical patent challenges globally.
+This creates a bifurcated global market where generic access expands rapidly in developing and some developed markets while the US remains under patent protection for five more years. The ruling's 'evergreening' language signals judicial skepticism toward defensive IP strategies that extend monopolies beyond primary patent terms, potentially influencing future pharmaceutical patent challenges globally.
+
+## Supporting Evidence
+
+**Source:** Apotex tentative approval timing; international generic launch comparison
+
+Apotex US tentative approval (April 10, 2026) is the domestic counterpart to international generic launches—US generic machinery is moving in parallel with India/Canada/China/Brazil/Turkey launches, but US commercial entry delayed 5-7 years by patent barriers while international markets already have generic access. The speed of tentative approval (21 days post-patent expiration) suggests Apotex filed ANDA well in advance, indicating generic competition pressure is real and immediate in legal sense even if commercial launch is years away.

entities/health/apotex.md

@@ -0,0 +1,27 @@
+---
+type: entity
+entity_type: company
+name: Apotex Inc.
+domain: health
+status: active
+founded: null
+headquarters: Canada
+website: https://www.apotex.com
+tags: [generic-pharmaceuticals, semaglutide, GLP-1, biosimilar]
+---
+
+# Apotex Inc.
+
+Canadian generic pharmaceutical manufacturer.
+
+## Overview
+
+Apotex is a generic pharmaceutical company that received the first US FDA tentative approval for generic semaglutide injection in partnership with Orbicular Pharmaceutical Technologies.
+
+## Timeline
+
+- **2026-04-10** — Received first US FDA tentative approval for generic semaglutide injection (ANDA) in partnership with Orbicular Pharmaceutical Technologies. As first ANDA filer, would receive 180 days of market exclusivity upon commercial launch. Tentative approval confirms application meets FDA standards but does not permit marketing due to Novo Nordisk patent barriers extending to December 5, 2031.
+
+## Strategic Position
+
+First-mover position in US generic semaglutide market with regulatory approval complete but commercial launch blocked by patent thicket. Realistic market entry: 2031-2033.

entities/health/orbicular-pharmaceutical-technologies.md

@@ -0,0 +1,23 @@
+---
+type: entity
+entity_type: company
+name: Orbicular Pharmaceutical Technologies
+domain: health
+status: active
+founded: null
+headquarters: null
+website: null
+tags: [generic-pharmaceuticals, semaglutide, GLP-1, formulation]
+---
+
+# Orbicular Pharmaceutical Technologies
+
+Pharmaceutical formulation development company.
+
+## Overview
+
+Orbicular Pharmaceutical Technologies partnered with Apotex on the development of generic semaglutide injection that received first US FDA tentative approval.
+
+## Timeline
+
+- **2026-04-10** — Partnership with Apotex received first US FDA tentative approval for generic semaglutide injection (ANDA). Orbicular provided formulation development expertise for the generic version.